NASDAQ:PTI - Proteostasis Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$9.01
▲ +0.03 (0.33%)
Get New Proteostasis Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PTI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PTI

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Proteostasis Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $9.01.

This chart shows the closing price for PTI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Proteostasis Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/29/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/14/2020Piper SandlerUpgradeNeutral ➝ OverweightHigh
8/24/2020Piper SandlerDowngradeOverweight ➝ NeutralHigh
8/11/2020HC WainwrightReiterated RatingBuyMedium
6/4/2020Cantor FitzgeraldReiterated RatingBuy$4.00Medium
6/4/2020Piper SandlerReiterated RatingOverweight ➝ Market Perform$3.00Medium
4/24/2020Royal Bank of CanadaReiterated RatingBuy$7.00Low
2/24/2020Piper SandlerReiterated RatingBuy$4.00High
12/23/2019HC WainwrightReiterated RatingBuy$8.00High
12/17/2019Piper Jaffray CompaniesReiterated RatingBuy$4.00Medium
10/18/2019Cantor FitzgeraldReiterated RatingOverweightLow
8/9/2019HC WainwrightReiterated RatingBuyHigh
5/9/2019Piper Jaffray CompaniesLower Price TargetOverweight$5.00High
3/25/2019Cantor FitzgeraldReiterated RatingBuy$14.00High
12/17/2018Cantor FitzgeraldReiterated RatingBuy$21.00High
11/6/2018Cantor FitzgeraldInitiated CoverageBuy$21.00High
10/29/2018Piper Jaffray CompaniesInitiated CoverageOverweight$14.00High
10/18/2018HC WainwrightReiterated RatingBuy$15.00High
10/18/2018Royal Bank of CanadaUpgradeSector Perform ➝ OutperformHigh
6/7/2018Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$11.00 ➝ $5.00High
3/9/2018Royal Bank of CanadaInitiated CoverageOutperform$11.00High
12/19/2017HC WainwrightReiterated RatingBuy$15.00Low
12/12/2017SVB LeerinkBoost Price Target$6.00 ➝ $8.00High
12/12/2017Robert W. BairdBoost Price TargetOutperform$13.00 ➝ $25.00High
8/16/2017SVB LeerinkReiterated RatingOutperform$17.00 ➝ $9.00High
6/30/2017HC WainwrightReiterated RatingBuy$15.00High
4/2/2017Robert W. BairdReiterated RatingOutperform$13.00High
1/24/2017HC WainwrightReiterated RatingBuy$15.00N/A
10/30/2016HC WainwrightSet Price TargetBuy$15.00N/A
8/12/2016SVB LeerinkReiterated RatingBuy$20.00N/A
(Data available from 7/23/2016 forward)
Proteostasis Therapeutics logo
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $9.01
Low: $8.66
High: $9.13

50 Day Range

MA: $11.24
Low: $1.00
High: $22.42

52 Week Range

Now: $9.01
Low: $0.87
High: $2.72

Volume

85,362 shs

Average Volume

1,036,509 shs

Market Capitalization

$470.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16

Frequently Asked Questions

What sell-side analysts currently cover shares of Proteostasis Therapeutics?

The following equities research analysts have issued stock ratings on Proteostasis Therapeutics in the last year: HC Wainwright, Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for PTI.

What is the current price target for Proteostasis Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Proteostasis Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Proteostasis Therapeutics in the next year.
View the latest price targets for PTI.

What is the current consensus analyst rating for Proteostasis Therapeutics?

Proteostasis Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PTI will outperform the market and that investors should add to their positions of Proteostasis Therapeutics.
View the latest ratings for PTI.

What other companies compete with Proteostasis Therapeutics?

How do I contact Proteostasis Therapeutics' investor relations team?

Proteostasis Therapeutics' physical mailing address is 80 Guest Street Suite 500, Boston MA, 02135. The company's listed phone number is 617-225-0096 and its investor relations email address is [email protected] The official website for Proteostasis Therapeutics is www.proteostasis.com.